Tag:
Simponi
Latest Headlines
Latest Headlines
Merck to pay J&J $500M in Remicade settlement
Merck ( $MRK ) can breathe a bit easier now that arbitrators have determined the fates of Remicade and Simponi, the arthritis drugs the drugmaker co-markets with Johnson & Johnson ( $JNJ ). With
J&J pulls Simponi injectors on possible dosing defect
Another day, another Johnson & Johnson ( $JNJ ) recall. The company has now recalled lots of Simponi injection devices because of their potential to deliver a substandard dose of the arthritis
Analysts reassess Merck-Schering merger
The judgment of Merck's Schering-Plough merger hangs in the balance, analysts tell Reuters. If the company loses big in its negotiations over the rights to Remicade and its follow-up drug Simponi,
Merck's Remicade face-off puts $2.7B at risk
The showdown over Remicade approaches. Johnson & Johnson and Merck will tussle over rights to the blockbuster anti-inflammatory drug--and its successor Simponi--in arbitration later this month.
Remicade safe with Merck, Hassan says
It's been the usual parade of drug-company executives at this year's Reuters Health Summit--and the usual steady flow of newsworthy comments. Among those on tap yesterday: Fred Hassan, who was CEO of
TNF blockers get child cancer warning
FDA is tacking new, stronger warnings on TNF-alpha blockers. The new label language highlights an increased risk of cancer in children and adolescents who take the blockbuster meds. These drugs
J&J brings arbitrators into Remicade dispute
It's official: Johnson & Johnson has asked official arbiters to let it abandon its Remicade partnership with Schering-Plough. J&J contends that the Merck/Schering merger amounts to a "change
Abbott sues J&J over new Humira rival
Get ready for a battle in the rheumatoid arthritis segment. Johnson & Johnson's Centocor unit is prepping for a launch of its new Humira competitor Simponi, and Abbott Laboratories is not amused.
J&J, Schering biologic wins FDA approval
Johnson & Johnson and Schering-Plough have won FDA approval for Simponi (golimumab), an injectable biologic drug for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing
